Central Nervous System Blast Crisis in Chronic Myeloid Leukemia on Imatinib Mesylate Therapy: Report of Two Cases

  • Narayan Radhika
  • Mishra Minakshi
  • Mohanty Rajesh
  • Baisakh R. Manas
  • Mishra Deepak Kumar
Case Report

Abstract

Chronic myeloid leukaemia is a chronic myeloproliferative disorder characterised by a reciprocal translocation between chromosomes 9 and 22 and thereby formation of the Philadelphia chromosome. Imatinib mesylate (STI-571) is a potent and selective inhibitor of BCR-ABL tyrosine kinase and has emerged as a treatment of choice in chronic myeloid leukaemia (CML) patients in chronic phase. It has shown activity in CML patients in the chronic phase or blastic phase. However there is poor penetration of the central nervous system (CNS) by the drug or its active metabolites. Therefore the CNS acts as a sanctuary site for malignant cells for CML patients treated with Imatinib. We report cases of two CML patients on Imatinib therapy, who were in haematological remission but developed CNS disease.

Keywords

Chronic Myeloid Leukaemia Central Nervous System Blast Crisis Imatinib 

References

  1. 1.
    Alintas A, Cil T, Kilnic I, Kaplan MA, Ayyildiz O (2007) Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate: a case report. J Neurooncol 84:103–105CrossRefGoogle Scholar
  2. 2.
    Rajappa S, Uppin SG, Raghunadharao D, Rao S, Surath A (2005) Isolated central nervous system blast crisis in chronic myeloid leukaemia. Hematol Oncol 22:179–181CrossRefGoogle Scholar
  3. 3.
    Peggs K, Mackinnon S (2003) Imatinib mesylate: the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 348:1048–1050CrossRefPubMedGoogle Scholar
  4. 4.
    Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr (2003) The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101:5010–5013CrossRefPubMedGoogle Scholar
  5. 5.
    Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM et al (2004) Plasma and cerebrospinal fluid pharmacokinetics of Imatinib after administration to non-human primates. Clin Cancer Res 10:2525–2529CrossRefPubMedGoogle Scholar
  6. 6.
    Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Ch Duba H, Schneller F et al (2002) Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 117:623–625CrossRefPubMedGoogle Scholar
  7. 7.
    Leis JF, Stepan DE, Curtin PT, Peng B, Ford JM, Schubach SE et al (2001) Low penetration of imatinib (STI571) into the CSF indicates need for standard CNS prophylaxis in patients with CML lymphoid blast crisis and Philadelphia chromosome positive ALL. In: The Proceedings of the American Society of Hematology 43rd Annual Meeting, abstract no. 2593Google Scholar
  8. 8.
    Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein mediated efflux. J Pharmacol Exp Ther 304:1085–1092CrossRefPubMedGoogle Scholar
  9. 9.
    Pfeifer H, Wassmann B, Hoffman W-K, Komor M, Scheuring U, Bruck P et al (2003) Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with Imatinib mesylate. Clin Cancer Res 9:4674–4681PubMedGoogle Scholar
  10. 10.
    Kim HJ, Jung CW, Kim K, Ahn JH, Kim WS, Park K et al (2006) Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after Imatinib. J Clin Oncol 24:4028–4029CrossRefPubMedGoogle Scholar
  11. 11.
    Bornhauser M, Jenke A, Ritcher JF, Radke J, Schuler US, Mohr B et al (2004) CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 83:401–402CrossRefPubMedGoogle Scholar
  12. 12.
    Thavaraj V, Seth R (2008) Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate. World J Pediatr 4:145–147CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2011

Authors and Affiliations

  • Narayan Radhika
    • 1
  • Mishra Minakshi
    • 1
  • Mohanty Rajesh
    • 1
  • Baisakh R. Manas
    • 1
  • Mishra Deepak Kumar
    • 1
  1. 1.Department of PathologyTata Main HospitalJamshedpurIndia

Personalised recommendations